Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

Believing SCOT-HEART: New Analysis Probes Plausible Mechanisms of Benefit

Shelley Wood

October 14, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Conference News ESC 2019

Nonphysician, Community Intervention Curbs CV Risk Factors: HOPE 4

Michael O'Riordan

September 02, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

Smoking More Strongly Linked to Long-term Risks of PAD Than to Other Types of CVD

Todd Neale

July 24, 2019

News Daily News

Weight Gain After Smoking Cessation: No Link With Increased CVD Risk in Young People

L.A. McKeown

June 27, 2019

News Daily News

Smoking More Strongly Linked to STEMI in Women Than in Men

Marcus A. Banks

June 27, 2019

News Daily News

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

L.A. McKeown

April 03, 2019

News Conference News ACC 2019

New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead

Michael O'Riordan

March 17, 2019

News Conference News ISET 2019

PAD in the Spotlight: Awareness, Treatment Remain Low Despite Many Years of Research

Caitlin E. Cox

January 28, 2019

News Daily News

Aspirin as Primary Prevention Curbs CV Events but Ups Major Bleeding, Too: Meta-analysis

Caitlin E. Cox

January 24, 2019

News Daily News

Sex Disparities Seen in China for Patients With ACS

Todd Neale

January 23, 2019

News Daily News

Nicardipine Alleviates ‘Slow Flow’ in Chest-Pain Patients Without Obstructive CAD

Michael O'Riordan

January 03, 2019

Advertisement

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Believing SCOT-HEART: New Analysis Probes Plausible Mechanisms of Benefit

Recurrent Events Common Among Young Patients With CAD

Nonphysician, Community Intervention Curbs CV Risk Factors: HOPE 4

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Smoking More Strongly Linked to Long-term Risks of PAD Than to Other Types of CVD

Weight Gain After Smoking Cessation: No Link With Increased CVD Risk in Young People

Smoking More Strongly Linked to STEMI in Women Than in Men

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead

PAD in the Spotlight: Awareness, Treatment Remain Low Despite Many Years of Research

Aspirin as Primary Prevention Curbs CV Events but Ups Major Bleeding, Too: Meta-analysis

Sex Disparities Seen in China for Patients With ACS

Nicardipine Alleviates ‘Slow Flow’ in Chest-Pain Patients Without Obstructive CAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content